We are a pioneering presence in the provision of remote healthcare solutions for healthcare organisations, physicians, providers and health systems in the US. As a medical device and MedTech innovator we merge our cutting-edge technologies with best-in-class clinical expertise collaborating with healthcare providers and organisations to extend our clients’ healthcare reach into the community. By serving as an extension of our clients’ healthcare services into the community, Respiri is committed to revolutionising the healthcare landscape, one patient at a time.
With a disruptive business model as a remote healthcare provider our R&D sets us apart – we are the only provider of RPM programs for all major chronic conditions, including unique remote wheeze detection for respiratory disorders.
Respiri can help transform the way patients experience care and extend healthcare delivery beyond the clinic through a range of customisable reimbursement programs which are designed to optimise both patient care and the Returns on Healthcare Investments.
Through strategic partnerships, we ensure that our unique approach to remote healthcare seamlessly integrates into existing systems and workflows. This collaborative effort not only enhances patient outcomes but also optimises efficiency and reduces costs for healthcare organisations. We are strategically positioned to revolutionise chronic disease management globally.
A Lifelong Partner For Our Patients.
As a differentiated remote healthcare provider, our mission is to improve health outcomes for patients with chronic diseases from cardiovascular, diabetes, obesity and, exclusively, wheeze detection for respiratory disease.
We are Respectful
We are Accountable
We are One Team
We are Innovative
Respiri Limited (ASX:RSH, OTCQB:RSHUF) is an Australian e-Health SaaS company supporting respiratory health management focusing primarily on supporting the US healthcare market.
Respiri is listed on the Australian Securities Exchange (ASX) and trades on the OTCQB under the ticker “RSHUF” for North American based investors
